Skip to main content

Table 1 Demographics and clinical characteristics of patients with COVID-19

From: Implications of cardiac markers in risk-stratification and management for COVID-19 patients

  Total
(N = 2954)
Mild/Moderate
(N = 1439)
Severe/Critical
(N = 1515)
P value
Characteristics
Age (yr.)—median (Interquartile range [IQR]) 60 (50–68) 57(45–65) 63 (54–71)  < 0.001
Sex– no. (%) 1
 Male 1,493 (50.5%) 728 (50.6%) 765 (50.5%)  
 Female 1,461 (49.5%) 711 (49.4%) 750 (49.5%)  
Initial temperature (℃)
– median (IQR)
0.002
  ≤ 37.3– no. (%) 2,833 (95.9%) 1,398 (97%) 1,435 (94.7%)
 37.3–38– no. (%) 85 (2.9%) 25 (2%) 60 (4%)
 38 -39– no. (%) 35 (1.17%) 16 (1%) 19(1.2%)
  > 39– no. (%) 1 (0.03%) 0 (0%) 1 (0.1%)
Comorbidities—no. (%)
 Hypertension 889 (30%) 348 (24%) 541 (36%)  < 0.001
 Diabetes 401 (14%) 159 (11%) 242 (16%)  < 0.001
 Cardiovascular disease 330 (11%) 104 (7%) 226 (15%)  < 0.001
 Cerebrovascular disease 118 (4%) 34 (2%) 84 (6%)  < 0.001
 Cancer 74 (3%) 19 (1%) 55 (4%)  < 0.001
 Chronic obstructive pulmonary disease 139 (5%) 40 (3%) 99 (7%)  < 0.001
 Chronic renal disease 47 (2%) 14 (1%) 33 (2%) 0.012
 Chronic liver disease 76 (3%) 36 (3%) 40 (3%) 0.817
 Immunodeficiency 9 (0%) 4 (0%) 5 (0%) 1
Respiratory rate—median (IQR)  < 0.001
  > 24 breaths per min– no. (%) 132 (4%) 14 (1%) 118 (8%)
  ≤ 24 breaths per min–no. (%) 2,820 (95%) 1,425 (99%) 1,395 (92%)
Hospital stays—median (IQR) 13 (8–19) 12 (8–17) 14 (8–22)  < 0.001
Death—no. (%) 59(2%) 0 (0%) 59(4%)  < 0.001
Clinical symptoms—no. (%)
 Fever 2,149 (73%) 1,032 (72%) 1,117 (74%) 0.231
 Cough 2,062 (70%) 992 (69%) 1,070 (71%) 0.336
 Shortness of breath 1302 (44%) 608 (42%) 694 (46%) 0.05
 Chest tightness 1,137 (38%) 517 (36%) 620 (41%) 0.006
 Fatigue 669 (23%) 279 (19%) 390 (26%)  < 0.001
 Muscle soreness 118 (4%) 29 (2%) 89 (6%)  < 0.001
 Headache 17 (1%) 13 (1%) 4 (0%) 0.027
 Dizziness 26 (1%) 14 (1%) 12 (1%) 0.695
 Nausea 22 (1%) 12 (1%) 10 (1%) 0.671
 Vomiting 22 (1%) 11 (1%) 11 (1%) 1
 Diarrhea 64 (2%) 34 (2%) 30 (2%) 0.528
Radiological findings (N = 2567)—no. (%)
 Blurred edges 304 (12%) 118 (9.6%) 186 (14%)  < 0.001
 Lymph node enlargement 30 (1.2%) 18 (1.5%) 12 (0.9%) 0.202
 Ground glass opacity 2324 (91%) 1109 (90%) 1215 (91%) 0.304
 Cystic change 209 (8.2%) 81 (6.6%) 128 (9.6%) 0.006
 Airway obstruction 4 (0.16%) 2 (0.16%) 2 (0.15%) 1
 Consolidation 332 (13%) 115 (9.4%) 217 (16%)  < 0.001
 Fine reticular opacity 56 (2.2%) 17 (1.4%) 39 (2.9%) 0.01
 Lung texture increase 1529 (60%) 734 (60%) 795 (60%) 0.968
 Intralobular septal thickening 14 (0.55%) 4 (0.33%) 10 (0.75%) 0.183
 Pleural thickening 221 (8.6%) 72 (5.9%) 149 (11%)  < 0.001
 Pleural effusion 205 (8%) 34 (2.8%) 171 (13%)  < 0.001
 Bronchiectasis 53 (2.1%) 17 (1.4%) 36 (2.7%) 0.025
Viral load of throat swabs (N = 1476)—median (IQR)
 ORF1ab 37.7 (34.51–40.08) 37.85 (34.85–40.05) 37.62 (34.07–40.15) 0.258
N 36.33 (33.77–37.82) 36.4 (34.08–37.77) 36.28
(33.5–37.91)
0.762
Anti-SARS-Cov-2 IgG and IgM level—median (IQR)
 IgG level 139.49 (73.93–181.24) 141.33
(74.82–180.45)
137.64 (73.88–181.45) 0.864
 IgM level 26.88
(8.38–66.74)
26.46
(8.13–62.5)
27.32
(8.52–68.62)
0.337